New hope for Tough-to-Treat ovarian cancer: first patients sought for experimental injection
Disease control
Not yet recruiting
This is a first-in-human study to test the safety and find the right dose of an experimental drug called WSK-IM02 for women with recurrent ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll up to 36 participants who will receive the d…
Phase: PHASE1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC